OBJECTIVES: To study adverse side effects produced by the administration of Vermella Slim on body weight and different body systems.
BACKGROUND: Vermella Slim will be used in humans and therefore the vital importance of carrying out these first-step tests. They will not only guarantee the quality of the product but will also establish that there are no adverse side effects in humans who take the product. As discussed in numerous international works, the study of acute toxicity is indispensable, and guarantees (within the margin of error associated with the technique) that the potential for toxicity from the compounds that will be ingested or that may enter into the system accidentally will be learned. Describing oral acute toxicity in the international literature is a requirement that must be fulfilled for all products that are to be introduced in the market for the first time.